<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03251859</url>
  </required_header>
  <id_info>
    <org_study_id>CMUMK202H</org_study_id>
    <nct_id>NCT03251859</nct_id>
  </id_info>
  <brief_title>Effectiveness of Lower Maintenance Dose of Ticagrelor Early After Myocardial Infarction (ELECTRA) Pilot Study</brief_title>
  <official_title>A Randomized, Open-label, Pharmacodynamic and Pharmacokinetic Trial Assessing the Effect of Lowering Ticagrelor Maintenance Dose Early After Myocardial Infarction on Platelet Inhibition (ELECTRA Pilot Study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Collegium Medicum w Bydgoszczy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Collegium Medicum w Bydgoszczy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ELECTRA pilot study is a randomized, open-label, pharmacokinetic and pharmacodynamic
      trial designed to evaluate the effect of ticagrelor maintenance dose reduction on platelet
      inhibition in stable patients who recently underwent acute myocardial infarction and were
      treated with percutaneous coronary intervention.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 11, 2017</start_date>
  <completion_date type="Actual">February 23, 2018</completion_date>
  <primary_completion_date type="Actual">February 23, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet Reactivity Assessed with the VASP assay</measure>
    <time_frame>45 days</time_frame>
    <description>Platelet inhibition evaluated with the VASP assay 45 days after myocardial infarction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet Reactivity Assessed with Multiple Electrode Aggregometry</measure>
    <time_frame>45 days</time_frame>
    <description>Platelet inhibition evaluated with Multiple Electrode Aggregometry 45 days after myocardial infarction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With High Platelet Reactivity according to the VASP assay</measure>
    <time_frame>45 days</time_frame>
    <description>Number of Patients With High Platelet Reactivity according to the VASP assay 45 days after myocardial infarction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With High Platelet Reactivity according to Multiple Electrode Aggregometry</measure>
    <time_frame>45 days</time_frame>
    <description>Percentage of Patients With High Platelet Reactivity according to Multiple Electrode Aggregometry 45 days after myocardial infarction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of Ticagrelor</measure>
    <time_frame>45 days</time_frame>
    <description>Evaluation of ticagrelor plasma concentration 45 days after myocardial infarction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of AR-C124910XX</measure>
    <time_frame>45 days</time_frame>
    <description>Evaluation of ticagrelor active metabolite plasma concentration 45 days after myocardial infarction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Standard ticagrelor maintenance dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ticagrelor 90 mg twice daily for the first 45 days after myocardial infarction treated with percutaneous coronary intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reduced ticagrelor maintenance dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor 90 mg twice daily for the first 30 days after myocardial infarction treated with percutaneous coronary intervention, then reduction of the maintenance dose to ticagrelor 60 mg twice daily for the next 15 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 90 mg</intervention_name>
    <description>Ticagrelor 90 mg twice daily</description>
    <arm_group_label>Standard ticagrelor maintenance dose</arm_group_label>
    <arm_group_label>Reduced ticagrelor maintenance dose</arm_group_label>
    <other_name>Brilique 90 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 60 mg</intervention_name>
    <description>Ticagrelor 60 mg daily</description>
    <arm_group_label>Reduced ticagrelor maintenance dose</arm_group_label>
    <other_name>Brilique 60 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  provision of informed consent prior to any study specific procedures

          -  diagnosis of acute ST-segment elevation myocardial infarction or acute non-ST-segment
             elevation myocardial infarction according to the Third Universal Definition of
             Myocardial Infarction

          -  index event treatment with percutaneous coronary intervention

          -  male or non-pregnant female, aged 18-80 years old

        Exclusion Criteria:

          -  contraindications for ticagrelor

          -  further coronary revascularization planned during the first 45 days after myocardial
             infarction

          -  indications for chronic treatment with oral anticoagulant or low-molecular-weight
             heparin

          -  active bleeding

          -  history of intracranial hemorrhage

          -  recent gastrointestinal bleeding (within 30 days)

          -  history of coagulation disorders

          -  history of moderate or severe hepatic impairment

          -  history of major surgery or severe trauma (within 3 months)

          -  active neoplastic disease

          -  patient requiring dialysis

          -  chronic inflammatory disease

          -  current therapy with strong CYP3A inhibitors or strong CYP3A inducers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Jacek Kubica, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy, Uniwersytet Miko≈Çaja Kopernika w Toruniu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology Department, Dr. A. Jurasz University Hospital</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2017</study_first_submitted>
  <study_first_submitted_qc>August 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2017</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Collegium Medicum w Bydgoszczy</investigator_affiliation>
    <investigator_full_name>Jacek Kubica</investigator_full_name>
    <investigator_title>Prof. Jacek Kubica, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>platelet reactivity</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>antiplatelet therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

